Shares of EXAS.O reached a 52-week high today, buoyed by positive developments in the healthcare sector. The stock's upward momentum follows Molina Healthcare's recent contract win with the Florida Agency for Health Care Administration, valued at an estimated $5 billion for managed care services. This significant contract is expected to enhance Molina's market presence and improve health outcomes for Florida's pediatric population, potentially driving membership growth and premium increases.
Despite this positive news, EXAS.O's recent performance has been mixed, with a notable decline of 17.2% over the past three months. The stock's technical breakout signals a shift in investor sentiment, contrasting with competitors like Exact Sciences and IDEXX Laboratories, which have outperformed in the same period. Investors are closely monitoring these developments as they assess the implications for EXAS.O and the broader healthcare market.
Wall Street analysts forecast EXAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 100.20 USD with a low forecast of 78.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast EXAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 100.20 USD with a low forecast of 78.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
19 Hold
0 Sell
Hold
Current: 102.300
Low
78.00
Averages
100.20
High
105.00
Current: 102.300
Low
78.00
Averages
100.20
High
105.00
Evercore ISI
Outperform
to
In Line
downgrade
$105
2026-01-05
Reason
Evercore ISI
Price Target
$105
AI Analysis
2026-01-05
downgrade
Outperform
to
In Line
Reason
Evercore ISI downgraded Exact Sciences to In Line from Outperform with an unchanged price target of $105.
Stifel
Buy
to
Hold
downgrade
$80 -> $105
2025-11-28
Reason
Stifel
Price Target
$80 -> $105
2025-11-28
downgrade
Buy
to
Hold
Reason
Stifel downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $80, after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EXAS
Unlock Now
Piper Sandler
David Westenberg
Overweight -> Neutral
downgrade
$105
2025-11-24
Reason
Piper Sandler
David Westenberg
Price Target
$105
2025-11-24
downgrade
Overweight -> Neutral
Reason
Piper Sandler analyst David Westenberg downgraded Exact Sciences (EXAS) to Neutral from Overweight with a $105 price target after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
Canaccord
Buy
to
Hold
downgrade
$85 -> $105
2025-11-24
Reason
Canaccord
Price Target
$85 -> $105
2025-11-24
downgrade
Buy
to
Hold
Reason
Canaccord downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $85, after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
